Robert S. Mittleman

ORCID: 0000-0003-2957-2419
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Arrhythmias and Treatments
  • Cardiac pacing and defibrillation studies
  • Cardiac electrophysiology and arrhythmias
  • Atrial Fibrillation Management and Outcomes
  • Hedgehog Signaling Pathway Studies
  • Genetic and Kidney Cyst Diseases
  • Genetic Syndromes and Imprinting
  • Lipoproteins and Cardiovascular Health
  • Gastroesophageal reflux and treatments
  • Cardiovascular Function and Risk Factors
  • Cardiac Valve Diseases and Treatments
  • Cardiac Structural Anomalies and Repair
  • Helicobacter pylori-related gastroenterology studies
  • Cancer, Lipids, and Metabolism
  • Liver Disease Diagnosis and Treatment
  • Lipid metabolism and disorders
  • RNA Research and Splicing
  • Liver Disease and Transplantation
  • Eosinophilic Esophagitis
  • RNA modifications and cancer
  • Digestive system and related health
  • Orthopaedic implants and arthroplasty
  • Cardiac Imaging and Diagnostics
  • Heart Failure Treatment and Management
  • Cardiovascular and exercise physiology

Jazz Pharmaceuticals (United States)
2021-2023

Rhythm (United states)
2021-2023

Jazz Pharmaceuticals (Italy)
2022

Ironwood Pharmaceuticals (United States)
2016-2020

Cyclerion (United States)
2020

Genesys (United States)
2016

Robert Morris University Illinois
2014-2016

Oregon Medical Research Center
2012-2013

University of Massachusetts Chan Medical School
1992-1996

Johns Hopkins University
1995

To evaluate the efficacy and safety of extended dosing with mipomersen in patients familial hypercholesterolaemia (HC) taking maximally tolerated lipid-lowering therapy. A planned interim analysis an ongoing, open-label extension trial (n = 141) HC receiving a subcutaneous injection 200 mg weekly plus therapy for up to 104 weeks. The mean changes low-density lipoprotein cholesterol (LDL-C) from baseline weeks 26 130), 52 111), 76 66), 53) were −28, −27, −28%; apolipoprotein B −29, −30, −31%,...

10.1093/eurheartj/eht549 article EN European Heart Journal 2013-12-23

<h3>Importance</h3> Heart failure with preserved ejection fraction (HFpEF) is often characterized by nitric oxide deficiency. <h3>Objective</h3> To evaluate the efficacy and adverse effects of praliciguat, an oral soluble guanylate cyclase stimulator, in patients HFpEF. <h3>Design, Setting, Participants</h3> CAPACITY HFpEF was a randomized, double-blind, placebo-controlled, phase 2 trial. Fifty-nine sites enrolled 196 heart at least 40%, impaired peak rate oxygen consumption (peak...

10.1001/jama.2020.16641 article EN JAMA 2020-10-20

Background & AimsRefractory gastroesophageal reflux disease (GERD) reduces quality of life and creates significant financial burden on the health care system. Approximately 30% patients with GERD who receive label-dose proton pump inhibitors (PPIs) still have symptoms. We performed a trial to evaluate efficacy safety IW-3718, bile acid sequestrant, as an adjunct PPI therapy.MethodsWe multicenter, double-blind, placebo-controlled trial, from March 2016 through April 2017, 280 confirmed GERD....

10.1053/j.gastro.2020.02.031 article EN cc-by-nc-nd Gastroenterology 2020-02-22

Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with hyperphagia, pathologic insatiable hunger, due to impaired signaling in the melanocortin-4 receptor (MC4R) pathway. The impact of hyperphagia on lives patients BBS and their families has not been fully characterized.Patients or caregivers who participated clinical trials MC4R agonist setmelanotide (NCT03013543 NCT03746522) were included this qualitative study. Telephone interviews conducted using semistructured interview...

10.1007/s12325-023-02443-y article EN cc-by-nc Advances in Therapy 2023-03-24

Although radiofrequency catheter ablation has undergone explosive growth as the treatment for a variety of arrhythmias, limiting factor with existing delivery system been relatively small size lesions, which appears to be in part due coagulum formation around tip, producing rise impedance and energy delivery. In order test hypothesis that infusion saline during current application can increase lesion decrease incidence rise, ten dogs were each given two lesions left ventricular endocardium....

10.1111/j.1540-8159.1995.tb04743.x article EN Pacing and Clinical Electrophysiology 1995-05-01

We report a case in which permanent pacemaker implantation using conventional subclavian approach on the throwing side of an avid Softball player resulted complete transection ventricular lead and severe damage to atrial lead. The site fracture suggested that both leads were crushed between clavicle first rib as result frequent repetitive arm movement. This illustrates importance selection correct for pacing insertion.

10.1111/j.1540-8159.1992.tb03132.x article EN Pacing and Clinical Electrophysiology 1992-09-01

A healthy 37‐year‐old male presented with a history of frequent palpitations and sustained wide QRS complex tachycardia right bundle branch block left axis morphology. Serial electrophysiological studies revealed two inducible tachycardias, which were shown to represent atrioventricular nodal reentrant idiopathic ventricular tachycardia. Transformation from one the other occurred spontaneously as well following atrial or pacing. Radiofrequency catheter ablation slow pathway resulted in cure...

10.1111/j.1540-8159.1994.tb01402.x article EN Pacing and Clinical Electrophysiology 1994-03-01

Radiofrequency catheter ablation of the atrioventricular janction is usually achieved from either right or left junction. We describe a new approach in which junction was successfully ablated supravalvular region noncoronary cusp aortic valve an unusual patient whom conventional approaches were unsuccessful.

10.1111/j.1540-8159.1994.tb01478.x article EN Pacing and Clinical Electrophysiology 1994-06-01

Abstract Objective Bardet-Biedl syndrome (BBS) is a rare genetic disease characterized by hyperphagia (pathologic insatiable hunger) and early-onset, severe obesity believed to be driven impaired signaling in the melanocortin-4 receptor (MC4R) pathway. In Phase 2 pivotal 3 trial, treatment with MC4R agonist setmelanotide produced beneficial reductions weight, body mass index (BMI), BMI Z score, hunger patients BBS at ∼1 year. The current analysis first assess continued long-term efficacy of...

10.1210/jendso/bvac150.029 article EN cc-by-nc-nd Journal of the Endocrine Society 2022-11-01
Coming Soon ...